Stock Events

Stock Events

Ovid Therapeutics 

€2.38
0
+€0+0% Friday 06:05

Statistics

Day High
2.38
Day Low
2.38
52W High
2.38
52W Low
0.24
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-0.11
-0.05
-0
0.05
Expected EPS
-0.10610646212
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1OT.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics competes in the rare diseases space, including treatments for neurological disorders, overlapping with Ovid's focus areas.
Biogen
BIIB
Mkt Cap25.38B
Biogen has a strong portfolio in neurology and rare diseases, making it a direct competitor to Ovid Therapeutics.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including therapies for neurological disorders, competing with Ovid's approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics for genetic and rare diseases, including neurological conditions, competing with Ovid.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.71B
Acadia Pharmaceuticals specializes in CNS disorders, including rare neurological conditions, making it a competitor to Ovid.
Anavex Life Sciences
AVXL
Mkt Cap273.38M
Anavex Life Sciences Corp. focuses on developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, competing with Ovid.
Neurocrine Biosciences
NBIX
Mkt Cap12.94B
Neurocrine Biosciences targets neurological and endocrine diseases, including treatments that could compete with Ovid's products.

About

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Show more...
CEO
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Employees
23
Country
United States
ISIN
US6904691010

Listings

STU
DE
1OT.STU
MU
DE
1OT.MU
XNAS
US
OVID
F
DE
1OT.F

0 Comments

Share your thoughts

FAQ

What is Ovid Therapeutics stock price today?▼
The current price of 1OT.MU is €2.38 EUR — it has increased by +0% in the past 24 hours. Watch Ovid Therapeutics stock price performance more closely on the chart.
What is Ovid Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ovid Therapeutics stocks are traded under the ticker 1OT.MU.
When is the next Ovid Therapeutics earnings date?▼
Ovid Therapeutics is going to release the next earnings report on May 13, 2026.
What were Ovid Therapeutics earnings last quarter?▼
1OT.MU earnings for the last quarter are 0.05 EUR per share, whereas the estimation was -0.1 EUR resulting in a +151.25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Ovid Therapeutics have?▼
As of April 13, 2026, the company has 23 employees.
In which sector is Ovid Therapeutics located?▼
Ovid Therapeutics operates in the Health & Wellness sector.
When did Ovid Therapeutics complete a stock split?▼
Ovid Therapeutics has not had any recent stock splits.
Where is Ovid Therapeutics headquartered?▼
Ovid Therapeutics is headquartered in New York, United States.